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Genome wide association study
Risk factorWhite matter lesions are a frequent phenomenon in the elderly and contribute to the development of disability.
The mechanisms underlying these brain lesions are still not fully understood with age and hypertension being
the most well established risk factors. The heritability of white matter lesions is consistently high in different
populations. Candidate gene studies strongly support the role of genes involved in the renin–angiotensin system,
as well as Notch3 signaling. The recent genome wide association study by the CHARGE consortium identiﬁed
a novel locus on chromosome 17q25 harboring several genes such as TRIM65 and TRIM47 which pinpoint to
possible novel mechanisms leading to white matter lesions.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
White matter lesions (WML) occur at high frequencies in routine
magnetic resonance imaging (MRI) scans of elderly persons. In
population-based studies the prevalence of any WML varies between
45% and 95%. Depending on the composition of the investigated
cohorts 12 to 33% of subjects have severe changes [1]. According to
location patterns WML can be separated in perventricular and deep/
subcortical abnormalities (Fig. 1).
Pathological correlations demonstrated that this nosological dis-
tinction reﬂects etiological differences. Table 1 summarizes the ﬁndings
of previous histopathological correlations.
As can be seen from this table periventricular hyperintensities in-
cluding caps around the ventricular horns, periventricular lining and
halos are likely to be of non-vascular originwhile deep and subcortical
WML are often ischemic lesions and there exists a continuum in sever-
ity ranging from punctuate to early conﬂuent and conﬂuent changes.
Punctate lesions often represent widened perivascular spaces only.
By contrast, early conﬂuent and conﬂuent abnormalities correspond
to incomplete ischemic tissue destruction including demyelination,
axonal degeneration, gliosis and focal transitions to true infarctions.
Early conﬂuent and conﬂuent changes progress rapidly over time [7]
and these lesion types often lead to clinical consequences including
cognitive decline, depression, gait disturbances, and urinary inconti-
nence [8–11]. The LADIS study has shown that early conﬂuent and
conﬂuent WML are also important predictors of disability [12].gy and Biochemistry, Center of
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C BY-NC-ND license.The genetic rawmodel for cerebral small vessel disease is Cerebral
Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL) [13]. CADASIL has been reported in
more than 500 families worldwide. The west of Scotland registry esti-
mated the prevalence of NOTCH3 gene mutations, which are respon-
sible for the disease, to be 4.14 per 100000 subjects in the general
population [14]. The MRI abnormalities seen in CADASIL patients are
strikingly similar to changes seen in sporadic small vessel disease.
MRI changes in CADASIL precede the onset of other symptoms by
10–15 years. The earliest and most frequent abnormalities are WML.
Just like in age-related WML CADASIL white matter abnormalities
ﬁrst appear as punctuate changes often in periventricular areas and
later becomemore diffuse, mostly symmetrical. Involvement of the ex-
ternal capsule is less frequent in age-related white matter diseases, but
the most distinguishing MRI ﬁnding in CADASIL is the involvement of
the anterior part of the temporal lobes [15].
In genetic studies WML have been either deﬁned by their localiza-
tion (periventricular or deep/subcortical) or severity, which can be
assessed visually or by semiautomatic volumemeasurement resulting
in a quantitative trait [16–18]. The etiology ofWML is still incomplete-
ly understood. Conventional risk factors such as age and hypertension
explain only a small proportion of the occurrence of WML [19]. Yet,
WML load is highly heritable [20–22] and numerous investigators
used genetic approaches to further explore genetic factors.
2. Heritability of WML
The heritability of a trait gives the proportion of the total phenotypic
variance (Vp) in the population which can be explained by genetic
differences among individuals (Vg). Importantly, the heritability index
is a quotient (h2=Vg/Vp) and its estimate is high, when there is a
Fig. 1.White matter lesions (WML) in T2-weighted FLAIR MRI scans. Panel A shows periventricular WML: from left to right caps, pencil-thin lining and halo. Panel B shows deep or
subcortical WML: from left to right punctate, early-conﬂuent and conﬂuent lesions.
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there is low phenotypic variability due to environmental factors in a
population. Therefore heritability indices strictly apply to the popula-
tion they have been estimated for. So far heritability estimates for
WML load have been reported in elderly male twins [20], in a large
population based sample of middle aged–elderly sibships [21], within
non-hispanic white and black hypertensive siblings [22,23], and in sib-
lings discordant for Alzheimer disease [24]. In spite of major differences
in the design of these studies, heritability estimates were comparable,
within the range of 50–80%. The heritability of WML may depend on
gender and age as suggested by the Framingham study [21]. A bivariate
heritability analysis, where the genetic correlation between WML load
and total and lobar brain volumes has been estimated, indicated that
there may be common genetic inﬂuences onWML volume and speciﬁc
brain regions such as frontal lobe volume and parietal lobe volume [25].
The Genoa (Genetic Epidemiology Network of Arteriopathy) study
reported signiﬁcant genetic correlations for WML with mean arterial
pressure and with pulse pressure in non-Hispanic white subjects withTable 1
The histopathological correlates of different types of white matter lesions.
Study Sample Main ﬁnding
Fazekas 1991 [2] 2 subjects without and 4 with neurologic disease Punctate lesi
and rarefacti
Chimowitz 1992 [3] 7 subjects with neurologic disease Periventricul
Periventricul
Punctate DW








Munoz 1993 [5] 2 Alzheimer cases and 13 controls Punctate rela
Extensive wh
or vascular w
Fernando 2006 [6] 99 demented subjects and 108 controls Wall thickenessential hypertension, indicating shared genetic components between
WML and blood pressure traits [23].
3. Dissecting the genetic architecture of WML
The consistently high heritability index reported for WML indicates
that genetic variants play an important role in the development of these
lesions. Different genetic variations in the human genome, such as sin-
gle nucleotide polymorphisms (SNPs), copy number variations (CNVs),
and epigenetic modiﬁcations may account for the genetic component.
The majority of the studies tested common SNPs (minor allele frequen-
cy, MAF≥5%) in the nuclear genome, one study investigated common
SNP in the mitochondrial genome [26] and one study systematically
tested one candidate gene, NOTCH3 for both common and rare SNPs
[27]. There are two alternative hypotheses existing to explain the
genetics of common diseases. The “common disease common variant”
hypothesis states that common genetic variants in the population
with relatively small effect sizes, typically odds ratios (OR)b2, explains
ons relate to perivascular damage with lipohyalinosis, atrophic neuropil
on of myelinated ﬁbers, 2 patients had cortical heterotopia.
ar rims relate to ependymal loss and subependymal gliosis.
ar caps relate to myelin pallor.
MH are widened perivascular spaces.
ar rims: Smooth myelin pallor, loose ﬁbers, tortuous venules, no arteriolosclerosis,
of ependym with mild-moderate gliosis.
iventricular lesions have varying ﬁber loss, gliosis and cavitation with lipohyalinosis
atter lesions: Punctate: no ischemic changes; demyelination, atrophic neuropil
yalionotic arterioles and perivenous damage.
nt: perivascular rarefaction of myelin, mild to moderate ﬁber loss, varying gliosis.
regular areas of incomplete parenchymal destruction with focal transitions to true
tes to widened perivascular spaces.
ite matter lesions are broad areas of loss of myelin, axons, and gliosis. No infarction
all changes.
ing, dilated perivascular spaces in WMH, ependym denudation in PVH.
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supposes that common diseases can be explained by rare variants (MAF
≤1–5%) segregating in families and enhancing the risk of their carriers
substantially (OR>2). Linkage studies investigate the co-segregation of
markers and phenotype in family-based settings and have highest
power to test the “common disease rare variant” hypothesis. Associa-
tion studies performed in unrelated subjects have high power to iden-
tify common alleles with small effect sizes. In spite of the success in
detecting many new loci by GWA studies, these common variants
often explain only a small proportion of the variation and are not useful
in clinical settings. Although linkage studies had detected signiﬁcant
loci for WML, genetic variants responsible for the linkage signals have
not yet been identiﬁed. With the evolving ‘next-generation’ DNA
sequencing techniques, sequencing these regions in a large number of
individuals became feasible. Rare variants seem to be quite common
in the general population [28], and it is now possible to combine new
DNA sequencing methods with linkage studies to identify rare causal
variants with a large effect size.
4. Linkage studies
So far signiﬁcant logarithm of the odds (LOD) scores for WML
has been found at 4 centiMorgan (cM) on chromosome 4 [29,30] in
healthy elderly white subjects, and at chromosome 1q24 in hyperten-
sive sibships [23]. Suggestive LOD scores by these studies have been
reported at 95 cM on chromosome 17 (LOD=1.78) [29], at 118 cM
on chromosome 11, and at 13 cM on chromosome 21 in white, and
at 36 cM on chromosome 22 as well as at 58 cM on chromosome 21
in black subjects [23]. Bivariate linkage studies identiﬁed signiﬁcant
(chromosome 1q24) and suggestive (chromosome 1q42, 10q22-q26,
15q26) shared loci for WML volumes and BP measurements, such as
pulse pressure and systolic blood pressure, indicating the presence
of genes with pleiotropic effects at these regions [23,31].
5. Candidate gene association studies
For more than a decade, the only feasible approach to identify ge-
netic variants for WML was the candidate gene approach. According
to a recent review 46 candidate gene studies investigating variants
in 19 genes have been performed [32]. Here we focus on those genetic
variants which are strongly supported by replication studies or func-
tional data.
5.1. Genes involved in blood pressure regulation
The renin–angiotensin system (RAS) is an excellent candidate for
WML, as it is a major regulator of systemic blood pressure, and cerebral
blood ﬂow [33]. Plasma angiotensinogen (AGT) synthesized by the liver
is processed to angiotensin II (Ang II) by the serial action of renin and
angiotensin-converting enzyme (ACE). Ang II exerts its effect through
the angiotensin receptors (AGTR). The association of ACE I/D polymor-
phism with WML had been investigated in nine studies including
2396 individuals. Uponmeta-analysis the DD genotype remained a sig-
niﬁcant predictor of WML (OR=1.95; 95% CI 1.09:3.48) [32]. The most
frequently investigated SNP in the AGT gene isM235T.Meta-analyses of
6 candidate gene studies including 2702 individuals showed no effect of
this SNP onWML [32]. In contrast, linkage studies repeatedly implicated
the AGT locus (1q42) [23,31] and the recent GWA study had replicated
the association between the 235T allele and WML [34]. Most probably
the 235T is not by itself a causal variant, but rather is in linkage disequi-
librium (LD) with functional variants in its neighborhood. One such
variant might be a haplotype (-6:a, -20:c, -153:g, -218:g) at the AGT
promoter, which signiﬁcantly enhanced the risk for WML. The effect
was independent of hypertension [35].We later showed that the haplo-
type enhances the basal transcriptional activity of the AGT promoter in
astrocytes, which are the major source of AGT in the brain but not inhepatocytes [36], suggesting that its association withWML is mediated
by altered activity of the cerebral RAS. Recently, a longitudinal study
reported that progression rate of WML in elderly men is inﬂuenced by
polymorphisms in the AGTR1 and AGTR2 genes. Homozygotes for the
1166A allele at AGTR1 showed less change over time than 1166C car-
riers [37]. There is also some indication for interaction onWMLbetween
the 573T allele at the AGTR1 gene and the 235T allele at the AGT gene
[38].
5.2. Genes involved in vascular dysfunction
Chronic hypoperfusion and impaired cerebral auto-regulation are
considered to be important contributors to the development of WML.
Recently, Markus reviewed studies investigating endothelial activation
and dysfunction in cerebral small vessel disease including also candi-
date genes such as ET1, MHTFR, NOS1 [39]. Due to small sample size of
the studies and lack of replications, there is little statistical evidence
presently that these genes harbor causal variants for WML. Also none
of these genes had been indicated by the recent GWA study [34].
CADASIL is a monogenic form of systemic small vessel disease pri-
marily affecting the brain [15,40–45]. It is caused by mutations in the
NOTCH3 gene [42], which plays a key role in the functional and struc-
tural integrity of small arteries [46–48]. We recently sequenced the
promoter, coding and 3′-untranslated region of the NOTCH3 gene in
a community-dwelling elderly cohort and showed that the NOTCH3
gene is highly variable with both common and rare SNPs spreading
across the gene. Among the 9 common SNPs 4 were signiﬁcantly asso-
ciated with WML. The association was conﬁned to hypertensives. The
most signiﬁcant SNP, rs10404382 was replicated in the Cohorts for
Heart and Ageing Research in Genomic Epidemiology Consortium
(CHARGE) on an independent sample of 4773 stroke-free hyperten-
sive elderly individuals of European descent. We also found support
that rare SNPs might be relevant in WML. From the 33 rare SNPs that
were identiﬁed, 9 non-synonymous SNPs were only detected in sub-
jects with severe WML and 6 of these SNPs (H170R, P496L, V1183M,
L1518M, D1823N and V1952M) were predicted to be functional by
proteinmodeling tools. The results on NOTCH3 resemble other studies
on complex traits, such as dyslipidemia where genes carrying com-
mon variants associated with modest effect in the population also
carry rare variants with large effects segregating in families [49].
6. Genome wide association studies
GWA studies have become awell established and successful method
to identify genes for common diseases. In order to enhance the power,
results from different cohorts are combined inmeta-analyses. Although
there have been concerns regarding the effect of heterogeneity in
meta-analyses of GWA studies, it has been shown that the approach is
fairly robust, with little differences between the respective studies re-
garding different measurements of the trait, different environmental
exposures or different genotyping chips, etc. [50].
The recent GWA study onWML performed by the CHARGE consor-
tium [34], included 9361 elderly individuals of European descent from
7 community-based cohort studies: the Aging Gene-Environment
Susceptibility-Reykjavik Study, the Atherosclerosis Risk in Communi-
ties Study, the Austrian Stroke Prevention Study, the Cardiovascular
Health Study, the Framingham Heart Study, and 2 cohorts from the
Rotterdam Study. Genome wide signiﬁcant association was identiﬁed
for 6 SNPs mapping to a locus on chromosome 17q25. The ﬁndings of
the discovery meta-analyses had been conﬁrmed in an independent
sample of 1607 AGES-Reykjavik participants and in 1417 elderly
white participants from the 3C-Dijon Study in the original report
[34] and later in 1677 persons of the Rotterdam Study III [51]. The re-
gion on chromosome 17 is ~100 kb long and harbors several genes
with diverse functions such as the 2 tripartite motif-containing
genes (TRIM65 and TRIM47) the WW domain binding protein 2 gene
85P. Freudenberger et al. / Journal of the Neurological Sciences 322 (2012) 82–86(WBP2), the mitochondrial ribosomal protein L38 gene (MRPL38), the
Fas-binding factor 1 gene (FBF1), the acyl-coenzyme A oxidase 1 gene
(ACOX1) and the C-Elegans homolog (UNC13D) gene. The GWA study
identiﬁed 3 additional SNPs which reached highly suggestive p-values
of b5*10
−5 and were located within genes coding for the polyamine-
modulated factor 1 gene (PMF1), the collagen type XXV alpha gene
(COL25A1), and the methylenetetrahydrofolate dehydro-genase 1
gene (MTHFD1).
7. Summary
The last decade of research on the genetics ofWML showed that this
phenotype is highly heritable over different populations and subgroups.
Candidate gene studies provided strong evidence for at least two path-
ways involved inWML, namely for the renin angiotensin system and for
the Notch3 signaling pathway. The recent GWA study was successful in
identifying common variants at chromosome17 pinpointing to possible
novel mechanisms leading toWML. It also brought together the largest
population based cohorts on the ﬁeld to work together in a concerted
effort.
The presently identiﬁed genetic risk factors explain only a small
proportion of the heritability of WML and further larger studies are
needed to identify more common SNPs and to test their interactions
with genetic and environmental factors. Finding associations with
low frequency and rare variants will be certainly facilitated by the
comprehensive catalog of these variants by the 1000 Genomes Project
(http://www.1000genomes.org/page.php) and by the availability of
next generation sequencing methods allowing deep sequencing of re-
gions of interest, such as those identiﬁed by linkage or GWA studies
or sequencing the whole genome. There is also need for studies inves-
tigating other genetic variants such as structural variants and epige-
netic marks in WML.
Dissecting the genetic architecture ofWMLwill contribute to a bet-
ter understanding of the etiology of conditions characterized by WML
and may facilitate the identiﬁcation of new biomarkers and therapeu-
tic targets with implications to prevention, diagnosis and treatment of
stroke and dementia.
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